The University of Oxford has partnered with pharmaceutical giant AstraZenenca for the development, manufacture and large-scale distribution of the Covid-19 vaccine candidate that is currently being trialled in the UK.

The agreement was announced this morning, with the details set to be finalised in the coming weeks.

The move will allow for rapid vaccination around the world if the candidate proves to be effective, the university said.

Human trials of the vaccine developed by the University’s Jenner Institute began last week, with hundreds of people volunteering to be part of the study which received ¬£20million in Government funding.

Professor Sir John Bell, Regius Professor of Medicine at Oxford University described the partnership with AstraZeneca as a ‘major force in the struggle against pandemics’ for the foreseeable future.

The Oxford University vaccine is called ChAdOx1 nCoV-19 and is made from a weakened version of a common cold virus

The Oxford University vaccine is called ChAdOx1 nCoV-19 and is made from a weakened version of a common cold virus

The Oxford University vaccine is called ChAdOx1 nCoV-19 and is made from a weakened version of a common cold virus


The vaccine is called ChAdOx1 nCoV-19 and is made from a weakened version of a common cold virus (adenovirus) from chimpanzees that has been genetically changed so it is impossible for it to grow in humans. 

Clinical teams at the Oxford University’s Jenner Institute and Oxford Vaccine Group began developing the ChAdOx1 nCoV-19 vaccine in January.  

The team have gone through stages of vaccine development that usually take five years in just four months. 

They were a step ahead of other groups because they already had a base vaccine for similar coronaviruses. 

The intellectual rights to its vaccine are owned by the University of Oxford and a spin-out company called Vaccitech. 

The first part of the trial will involve 510 health volunteers aged between 18 and 55. 

Then the trial will move into older age groups, looking at the safety and immune response to the vaccine.

Half of all the trial volunteers will get the new coronavirus vaccine and the other half will get a vaccine licensed to protect against meningitis. Volunteers will not know what they are given. 

Speaking on BBC Radio 4’s Today programme, Sir John said he hoped that some results from a human trial of the vaccine would be available by the middle of June.

He told Today that the challenge now is to be able to manufacture at scale once it is approved by the regulators.

Sir John added: ‘We also want to make sure that the rest of the world will be ready to make this vaccine at scale so that it gets to populations in developing countries, for example, where the need is very great.

‘We really need a partner to do that and that partner has a big job in the UK because our manufacturing capacity in the UK for vaccines isn’t where it needs to be, and so we are going to work together with AstraZeneca to improve that considerably.’

It is the first such partnership to be formed since the Government launched the Vaccines Taskforce two weeks ago to help find a new coronavirus vaccine.

Both partners have agreed to operate on a not-for-profit basis for the duration of the pandemic, the university said, with only the costs of production and distribution being covered.

Health Secretary Matt Hancock said it was ‘hugely welcome news’ that Oxford University had come to an agreement with AstraZeneca to scale up its coronavirus vaccine.

He tweeted: ‘The Oxford vaccine is one of the most advanced in the world. Bringing together the best British science and the best of British business will give us the best possible shot at a vaccine.

‘The science is uncertain, and no vaccine may work, but this deal gives the UK the best chance we can of a breakthrough that could defeat this awful virus. I’m sending best wishes for good fortune to all involved – for the sake of the nation and indeed the whole world.’

It comes after the world’s largest vaccine maker yesterday warned no coronavirus jab will be ready to manufacture on a mass scale until late next year.

Emma Walmsley, chief executive of Brentford-based GlaxoSmithKline, said millions of doses would not be produced until the second half of 2021, ‘if things go right’.

In a separate promising development, major drug giant Pfizer yesterday announced it may have a coronavirus vaccine ready by the autumn.

The US-based company has already started mass manufacturing doses and is aiming to have ‘hundred of millions of doses’ ready by the end of the year.

Developing vaccinations usually takes many months or years but researchers are hurtling towards human trials.

They say the process has been made easier because the virus, scientifically known as SARS-CoV-2, is not mutating and is similar to other viruses seen in the past. 

Leave a Reply
You May Also Like

Moment union chief claims it will be the GOVERNMENT’S fault if people DIE during paramedics’ strikes

A union boss has claimed the government will be responsible if people…

Lymphoma drug outperforms Remdesivir against the COVID-19 virus

Since the beginning of the COVID-19 pandemic, experts have looked at ways…

Coronavirus: Sweden and Poland last European countries to peak

The only European countries that have not passed their coronavirus peak are…

Type 2 diabetes symptoms: The sign in your mouth you may have developed the condition

Type 2 diabetes can cause a wide range of symptoms, from peeing…